Evidence map›Paper›PMID 42369460›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.

Sebastian Gallon, Prince Baffour Tonto, Yifeng Ding, Guan-Hua Chen, Kailee Naito-Keoho, Carlos Brites, Eduardo Martins Netto, Wei-Kung Wang, Bobby Brooke Herrera

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sebastian GallonRutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA.
Prince Baffour TontoRutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA.
Yifeng DingRutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA.
Guan-Hua ChenDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Kailee Naito-KeohoDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Carlos BritesLaboratório de Pesquisa em Infectologia (LAPI)-School of Medicine, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Eduardo Martins NettoLaboratório de Pesquisa em Infectologia (LAPI)-School of Medicine, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Wei-Kung WangDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Bobby Brooke HerreraRutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA.ORCID 0000-0002-2438-6716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-dependent enhancement (ADE) is a major concern across orthoflavivirus infections, yet how multiple viral exposures shape enhancement risk remains incompletely understood. Here, we integrated serosurveillance from Saúde, Brazil with functional immunologic analyses to define how yellow fever virus (YFV)-associated orthoflavivirus immune histories influence ADE phenotypes. Using serocomplex-specific anti-premembrane antibody profiling validated by microneutralization assays, plasma samples were stratified into YFV-only, YFV+DENV, and YFV+DENV+ZIKV exposure groups. In Fcγ receptor-bearing U937 cells, YFV-only plasma demonstrated minimal enhancement activity, whereas cumulative orthoflavivirus exposure generated broader ADE phenotypes across heterologous viruses. In

Indexed as

antibody-dependent enhancementdengue virus serotypes 1-4neutralizing antibodiesWestern blotyellow fever virusZika virus

Identifiers

PMID42369460
PMCPMC13308297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.